
Ethics approval received to test SPONTAN® in pulmonary arterial hypertension
LTR Pharma has received ethics approval for a clinical study of SPONTAN® in pulmonary arterial hypertension (PAH). PAH represents a significant global therapeutics market, estimated at US$8.0 billion in 2024 and forecast by third-party sources to reach up to US$17.9 billion by 2034. What is pulmonary arterial hypertension (PAH)? PAH is

